These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37492633)

  • 1. Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study.
    Dai MS; Chao TC; Chiu CF; Lu YS; Shiah HS; Jackson CGCA; Hung N; Zhi J; Cutler DL; Kwan R; Kramer D; Chan WK; Qin A; Tseng KC; Hung CT; Chao TY
    Ther Adv Med Oncol; 2023; 15():17588359231183680. PubMed ID: 37492633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.
    Jackson CGCA; Hung T; Segelov E; Barlow P; Prenen H; McLaren B; Hung NA; Clarke K; Chao TY; Dai MS; Yeh HT; Cutler DL; Kramer D; He J; Zhi J; Chan WK; Kwan R; Deva S
    Br J Clin Pharmacol; 2021 Dec; 87(12):4670-4680. PubMed ID: 33960504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
    Rugo HS; Umanzor GA; Barrios FJ; Vasallo RH; Chivalan MA; Bejarano S; Ramírez JR; Fein L; Kowalyszyn RD; Kramer ED; Wang H; Kwan MR; Cutler DL;
    J Clin Oncol; 2023 Jan; 41(1):65-74. PubMed ID: 35858154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
    Ma WW; Li JJ; Azad NS; Lam ET; Diamond JR; Dy GK; Opyrchal M; Zhi J; Kramer D; Chan WK; Cutler D; Kwan R; Adjei AA; Jimeno A
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):7-17. PubMed ID: 35731258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral docetaxel plus encequidar - a phase 1 clinical trial.
    Wang D; Hung N; Hung T; Eden K; Chan WK; Kwan R; Qin A; Chang C; Duffull S; Glue P; Jackson C
    Cancer Chemother Pharmacol; 2024 Sep; 94(3):475-481. PubMed ID: 38814342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
    Conlin AK; Seidman AD; Bach A; Lake D; Dickler M; D'Andrea G; Traina T; Danso M; Brufsky AM; Saleh M; Clawson A; Hudis CA
    Clin Breast Cancer; 2010 Aug; 10(4):281-7. PubMed ID: 20705560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
    O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y
    JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
    Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
    Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
    Inoue K; Kuroi K; Shimizu S; Rai Y; Aogi K; Masuda N; Nakayama T; Iwata H; Nishimura Y; Armour A; Sasaki Y
    Int J Clin Oncol; 2015 Dec; 20(6):1102-9. PubMed ID: 25967286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.
    Kruijtzer CM; Boot H; Beijnen JH; Lochs HL; Parnis FX; Planting AS; Pelgrims JM; Williams R; Mathôt RA; Rosing H; Schot ME; Van Tinteren H; Schellens JH
    Ann Oncol; 2003 Feb; 14(2):197-204. PubMed ID: 12562644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of home vs clinic administration of paclitaxel in metastatic breast cancer.
    Sharma D; Wojtynek J; Fox KM; Cooper C; Dokubo I
    Am J Manag Care; 2021 Feb; 27(2 Spec. No.):SP46-SP50. PubMed ID: 33395244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
    Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA;
    Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
    Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
    Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
    Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
    Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.
    Mayer EL; Scheulen ME; Beckman J; Richly H; Duarte A; Cotreau MM; Strahs AL; Agarwal S; Steelman L; Winer EP; Dickler MN
    Breast Cancer Res Treat; 2013 Jul; 140(2):331-9. PubMed ID: 23868188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
    Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
    Schwartzberg LS; Arena FP; Mintzer DM; Epperson AL; Walker MS
    Clin Breast Cancer; 2012 Apr; 12(2):87-93. PubMed ID: 22154117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
    Friedland DM; Dakhil S; Hollen C; Gregurich MA; Asmar L
    Cancer Invest; 2004; 22(3):374-82. PubMed ID: 15493358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer.
    Lee HJ; Heo DS; Cho JY; Han SW; Chang HJ; Yi HG; Kim TE; Lee SH; Oh DY; Im SA; Jang IJ; Bang YJ
    Cancer Res Treat; 2014 Jul; 46(3):234-42. PubMed ID: 25038758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.